IN THE STUDY Clause Samples

IN THE STUDY. While on the study, the risks are: • Loss of Confidentiality: Every precaution will be taken to remove identifying information from all data taken for this study, but absolute assurance of confidentiality cannot be given.
View SourceView Similar (3)
IN THE STUDY. This consent form contains important information to help you decide if you want to be in the study. If you have any questions that are not answered in this consent form, ask one of the study staff. Please answer YES or NO to the following questions:
View SourceView Similar (2)
IN THE STUDY. The overall experience of the ▇▇▇.▇▇ app enables users to earn points through their actions in the app. Points will be collected on an ongoing basis by the participant within the app. Cumulative points for this study will be 25,000 points (collected after the participant completes all study required procedures, including the final survey). Participants in this study who complete all the actions can convert these total 25,000 points to a one-time only ▇▇▇▇▇▇.▇▇▇ gift card of up to $250.00 in value through the link provided after the final survey. You will be offered a phone stand approximately $10 in value, if you need it. If you are invited to do the usability interview and complete the interview successfully, you will receive a one-time link for a total of $50, redeemable as a one-time ▇▇▇▇▇▇.▇▇▇ gift card. The principal investigator is an employee of ▇▇▇.▇▇ on whose app this study is being conducted and is being paid by the sponsor to conduct this research study.
View Source
IN THE STUDY. You might feel tired from the eye exams or study procedures. Also, the eye exams and measurements may pose risks because some devices come very close to or touch your eyes. There is a small chance that the instrument used could scratch the surface of your eye. If that occurs, it is usually minor. Also, you may experience blurred vision or discomfort from the numbing drop that the study doctor gives you. These could last up to 24 hours after the exam. Also, there is a risk of allergic reaction (itching, redness, burning, or mucous discharge) to the ingredients in the anesthetic (numbing) eye drop used in these evaluations. If experienced, this could last up to 12 hours. Because your eyes are numb, it’s important that you do not rub your eyes for at least 20 minutes after the exam. The orange-yellow (Fluorescein) dye that will be put in your eyes to evaluate the intraocular pressure (pressure inside your eye) may make your skin and bodily secretions and excretions, such as your tears or mucous, change color, or they may cause some irritation to your eyes. This effect is usually temporary and disappears within a day. Rarely, people can have an allergic reaction to fluorescein dye. This would usually involve itching, swelling, or redness. If you develop such a reaction, you will receive treatment. As with any allergy, more serious or life threatening reactions are possible. No adverse reactions (bad side effects) have been reported for the Canon HS100 OCT or Optovue RTVue XR devices. Because the Canon HS100 OCT device is investigational (not yet FDA-approved), all of its side effects may not be known. There may be rare and unknown side effects. You must tell the study doctor and staff if you experience any side effects. If you are not honest about your side effects, it may not be safe for you to be in the study.
View Source
IN THE STUDY. Part 1 (Cohorts 1-6) Payment Part 2 (Cohorts 7, 8, 9, and 10) Payment
View Source
IN THE STUDY. You may receive up to for being in the study. You will be paid per completed visit as follows: Screening Visit 1 Visit 2 Visit 3 Follow-up Telephone Call Total compensation for study completion will be up to for completion of all study visits and the
View Source
IN THE STUDY. I have read this consent form. I understand the purpose, procedures and risks as explained in this document. My questions have been answered to my satisfaction. I voluntarily agree to participate in this study. I know that I can stop participation at any time. I will be given a signed and dated copy of this agreement. Name of Study Subject (printed) Signature of Study Subject Date Name of Study Subject’s Partner (printed) – if applicable Signature of Study Subject’s Partner – if applicable Date I have discussed the research study with the subject and subject’s partner and explained to them in non-technical terms all of the information contained in this informed consent form, including any risks that may reasonably be expected to occur. I further certify that I encouraged the subject and the subject’s partner to ask questions and that all questions asked were answered. Printed Name of Person Explaining Consent Form Signature of Person Explaining Consent Form Date You will be given a signed and dated copy of this informed consent to keep.‌
View Source

Related to IN THE STUDY

  • Conduct of the Study 3.1 Athenex shall act as the sponsor of the Study and shall hold the IND/CTA relating to the Study; provided, however, that in no event shall Athenex file a separate IND/CTA for the Study unless required by Regulatory Authorities to do so. If a Regulatory Authority requests a separate IND/CTA for the Study the Parties will meet and mutually agree on an approach to address such requirement. 3.2 Athenex shall ensure that the Study is performed in accordance with this Agreement, the Protocol and all Applicable Law, including GCP. 3.3 Athenex shall ensure that all directions from any Regulatory Authority and/or ethics committee with jurisdiction over the Study are followed. Further, Athenex shall ensure that all Regulatory Approvals from any Regulatory Authority and/or ethics committee with jurisdiction over the Study are obtained prior to initiating performance of the Study. Athenex shall participate in and lead all discussions with any Regulatory Authority regarding the Study, provided, however, that Lilly shall have the right (but no obligation) to participate in any discussions with a Regulatory Authority, and prior review and approval of any written communications with a Regulatory Authorty, regarding matters related to the Lilly Compound. 3.4 Athenex shall maintain reports and all related documentation (paper or electronic versions as applicable) in good scientific manner and in compliance with Applicable Law. Athenex shall provide any Study information and documentation reasonably requested to enable Lilly to (i) comply with any of its legal and regulatory obligations, or any request by any Regulatory Authority, in each case, to the extent related to the Study or such the Lilly Compound, (ii) satisfy any contractual obligation to a subcontractor engaged pursuant to Section 2.4 hereof, and (iii) to determine whether the Study has been performed by Athenex in accordance with this Agreement. 3.5 Athenex shall ensure that all patient authorizations and consents, and all consents from other data subjects, for the processing, use and disclosure of their data and the Clinical Data, required under HIPAA, the EU Data Protection Directive, EU General Data Protection Regulation, and any other similar Applicable Law in connection with the Study, permit the use and sharing of the Clinical Data as set forth in this Agreement, including the sharing of Clinical Data with Lilly. 3.6 All Clinical Data, including raw data and results, generated under this Agreement, as well as the protocol(s), analyses, plans and any other documentation prepared by one or more of the Parties under this Agreement specifically for use in connection with the Study and related to the Lilly Compound, shall be jointly owned by Lilly and Athenex.

  • Scope of the Services UNOPS intends to retain the Contractor for the implementation of the Services, and the Contractor intends to provide the Services. The Contractor has represented to UNOPS that it has the appropriate experience, expertise, licences, and resources to undertake the Services and has agreed to undertake the Services in accordance with the Contract. In reliance on the Contractor’s representations UNOPS has entered into the Contract. The Contract sets out the terms and conditions upon which the Contractor will undertake the Services.

  • B1 The Services The Contractor shall supply the Services during the Contract Period in accordance with the Authority’s requirements as set out in the Specification and the provisions of the Contract in consideration of the payment of the Contract Price. The Authority may inspect and examine the manner in which the Contractor supplies the Services at the Premises during normal business hours on reasonable notice.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).